Universal antenatal human immunodeficiency virus (HIV) testing programme is cost-effective despite a low HIV prevalence in Hong Kong

Hong Kong Medical Journal

Volumn 13, Issue 3, 2007, Pages 199-207

  Lee, P M ^a   Wong, K H ^a  

^a Red Ribbon Centre   (Hong Kong)

Author keywords

Cost benefit analysis; Disease transmission, vertical; HIV infections; Mass screening; Quality adjusted life years

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INDINAVIR; LAMIVUDINE; NELFINAVIR; ZIDOVUDINE;

ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DELIVERY; DISEASE TRANSMISSION; FEMALE; FOLLOW UP; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HONG KONG; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNOASSAY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; OUTCOME ASSESSMENT; PRENATAL CARE; PRENATAL DIAGNOSIS; PUBLIC HOSPITAL; SENSITIVITY ANALYSIS;

ADULT; ANTI-HIV AGENTS; COST-BENEFIT ANALYSIS; DISEASE TRANSMISSION, VERTICAL; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HONG KONG; HUMANS; INFANT, NEWBORN; MASS SCREENING; PATIENT EDUCATION AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL CARE; PRENATAL DIAGNOSIS; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS;

EID: 34250360629     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Conner EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Group. N Engl J Med 1994;331:1173-80.
2. Mofenson LM, McIntyre JA. Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet 2000;355:2237-44.
3. Special Preventive Programme, Department of Health. Evaluation of effectiveness of universal HIV testing programme in Hong Kong. Hong Kong, Department of Health website: http://www.info.gov.hk/aids/pdf/g147.pdf. Accessed May 2005.
4. Scientific Committee on AIDS, Hong Kong Advisory Council on AIDS. Recommended clinical guidelines on the prevention of perinatal HIV transmission. Hong Kong, Advisory Council on AIDS website: http://www.info.gov.hk/aids/pdf/ g176.pdf. Accessed May 2005.
5. Scientific Committee on AIDS, Hong Kong Advisory Council on AIDS. 2003 Report on the implementation of the Universal Antenatal HIV Testing Programme in the Public Service. Hong Kong, Advisory Council on AIDS website: http://www.info.gov.hk/aids/pdf/g128/index.htm. Accessed June 2005.
6. Drug Formulary 2004/5. Hong Kong: Department of Health; 2005.
7. Graves N, Walker DG, McDonald AM, Kaldor JM, Ziegler JB. Would universal antenatal screening for HIV infection be cost-effective in a setting of very low prevalence? Modelling the data for Australia. J Infect Dis 2004;190:166-74.
8. Sculpher MJ, Gibb D, Ades AE, Ratcliffe J, Duong T. Modelling the costs of paediatric HIV infection and AIDS: comparison of infected children born to screened and unscreened mothers. AIDS 1998;12:1371-80.
9. Hong Kong Gazette. The fees payable for hospital services to be provided by public hospital. Hong Kong: Hong Kong SAR Government; 2003.
10. Hong Kong Gazette. A list of charges payable at Government polyclinics, clinics, dispensaries and other institutions. Hong Kong: Hong Kong SAR Government; 2003.
11. Hong Kong 2004 Population Census Survey Results. Hong Kong Census and Statistics Department website: http://www.info.gov.hk/censtatd/eng/hkstat/hkinf/ nat_account_index.html. Accessed May 2005.
12. Ades AE, Sculpher MJ, Gibb DM, Gupta R, Ratcliffe J. Cost effectiveness analysis of antenatal HIV screening in United Kingdom. BMJ 1999;319:1230-4.
13. Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States. J Acquir Immune Defic Syndr 2000;25:403-16.
14. Chau J, Cheung BM, McGhee SM, Lauder IJ, Lau CP, Kumana CR. Cost-effectiveness analysis of applying the Cholesterol and Recurrent Events (CARE) study protocol in Hong Kong. Hong Kong Med J 2001;7:360-8.
15. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 2001;19:1103-9.
16. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81.
17. Immergluck LC, Cull WL, Schwatz A, Elstein AS. Cost-effectiveness of universal compared with voluntary screening for human immunodeficiency virus among pregnant women in Chicago. Pediatrics 2000;105:E54.